Bielefeld-based start-up Semalytix participates in EU research project

Prêt-à-LLOD: Ready-to-use Multilingual Linked Language Data for Knowledge Services across Sectors - this is the name under which a research project was launched at the beginning of 2019 for which the European Commission is providing €3 million under the Horizon 2020 funding line. As a research-oriented company, Semalytix contributes its expertise in the field of multilingual text data analysis to a sub-project. €300,000 from the EU budget will go to the Bielefeld company.

Matthias Hartung, Chief Research and Development Officer (CRDO) at Semalytix, explains the project as follows: „An important strategic focus of the European Commission is the establishment of the Digital European Single Market as the online marketplace of the future. Multilingual procedures from language technology and artificial intelligence, as we develop them for the analysis of large amounts of text at Semalytix, will form a core competence in this area“.

Research partners of the project include renowned universities of international importance such as National University of Galway (coordinator), University of Saragossa, Polytechnical University of Madrid, Bielefeld University, Goethe University Frankfurt/Main and DFKI Berlin. In addition to the Bielefeld Semalytix GmbH the Semantic Web Company (Vienna), Oxford University Press (Oxford) and Derilinx (Dublin) act as industry partners in the project.

Founded in 2015, Semalytix works closely with global players in the pharmaceutical industry. Semalytix is developing a technology that allows automated real-time analysis of unstructured data from a wide variety of sources while at the same time achieving the quality and contextual understanding of manual evaluation by human experts. As added value, Semalytix’s analyses provide a deeper understanding of the core benefits of pharmaceutical products from a comprehensive perspective of all market players, including, for example, the needs of cancer patients. The aim is to achieve better medicines and more needs-based services on the part of pharmaceutical companies.